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display process are conducted in vitro, a variety of strat-
egies are possible, such as in vitro mutagenesis [15],
recombination [16], and nonsense suppression [17], that
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Pasadena, California 91125 are not easily available to approaches such as phage
display [6] or the yeast two-hybrid systems [18].
-lactam drugs are antibiotics widely used to treat
bacterial infections and function as irreversible inhibi-Summary
tors of the penicillin binding proteins (PBP) required for
bacterial cell wall synthesis [19]. Since the introductionThe chemical diversity of peptide and protein libraries
of these drugs, numerous bacterial strains have gainedgenerated from biological display systems is typically
resistance against them using a variety of mechanisms.confined to the 20 naturally occurring amino acids.
One of the most common modes of resistance is con-Here, we have developed a general strategy to intro-
ferred by -lactamase, an enzyme which hydrolyzesduce non-natural side chains into mRNA-display li-
these drugs by opening the lactam ring [20]. Clinically,braries via specific chemical derivatization. We con-
a variety of strategies have been pursued including thestructed a mRNA-display library containing 3  1012
use of irreversible -lactamase inhibitors [21] that aredifferent peptides bearing a pendant penicillin moiety
coadministrated with the drug. For example, Augmentinin a fixed position. In vitro selection using this hybrid
is a broad spectrum antibiotic that consists of a mixturepeptide-drug library resulted in novel inhibitors of the
of ampicillin and the irreversible -lactamase inhibitorStaphylococcus aureus penicillin binding protein 2a
clavulanic acid. However, these drugs can be useless(PBP2a). This strategy resulted in a penicillin-peptide
to treat infections resulting from several strains, suchconjugate that has at least 100-fold higher activity than
as methicillin-resistant Staphylococcus aureus (MRSA)the parent penicillin itself. Our approach provides a
[22], where resistance is conferred by PBP2a, a penicillinconvenient way to enhance the efficacy of known
binding protein that is sufficient for cell wall synthesisdrugs and facilitates the discovery of powerful new
even at drug concentrations where other penicillin bind-hybrid ligands with functionalities beyond those pro-
ing proteins are covalently inactivated [23–26]. Strainsvided by the 20 naturally occurring residues.
such as MRSA impose a serious health threat and neces-
sitate the development of more powerful antibiotics.
Introduction We were interested in using mRNA display to isolate
peptide-penicillin conjugates that could function against
Combinatorial peptide libraries are rich reservoirs for PBP2a, the primary -lactam-resistance determinant in
discovery of novel ligands against therapeutically inter- MRSA. Previously, we had used nonsense suppression
esting targets, including agonists [1] or antagonists of to insert the nonnatural residue biocytin into an mRNA
receptors [2], epitopes of antibodies [3], and inhibitors display library and select for its function [17]. Here, we
of enzymes [4]. Techniques such as phage display [5, demonstrate an alternative strategy incorporating a pen-
6], ribosome display [7, 8], and mRNA display [9, 10] icillin side chain into an mRNA display library via chemi-
can generate peptides that are physically associated cal derivatization and selecting for functional drug-pep-
with their own genes, making it feasible to identify mole- tide conjugates. This approach has allowed us to identify
cules with desired properties through iterative cycles of a series of novel penicillin derivatives (mol wt 1500;
enrichment and amplification. Because these libraries cf. vancomycin, mol wt 1449 g/mol) that inhibit Staph-
are made in biological systems, the chemical diversity ylococcus aureus PBP2a.
is generally restricted to the 20 naturally occurring amino
acids. By comparison, synthetic peptide libraries can
contain numerous nonstandard residues but typically Results and Discussion
represent much smaller sequence complexity than dis-
play approaches. Additionally, identification of active Constructing a mRNA Display Library Containing
molecules in synthetic libraries often requires complex a Penicillin Side Chain
deconvolution [11] or sophisticated encoding strategies We began by working to append penicillin to a mRNA
[12]. We have therefore been very interested in develop- display library. Previous work with penicillins indicated
ing approaches that allow nonnatural residues to be that numerous modifications have been made to the 6
incorporated into highly complex natural display li- position of the -lactam ring to enhance the pharmaco-
braries. kinetics and other properties of -lactam drugs [27]. We
The mRNA display approach allows libraries con- therefore constructed the cysteine-reactive penicillin
taining more than 1013 independent peptides or proteins derivative 6-bromoacetyl penicillanate (Figure 1A) to
to be constructed entirely in vitro, providing the highest allow the chemical diversity present in our peptide librar-
sequence diversity currently available with any method ies to be displayed in a similar fashion.
[13, 14]. Additionally, because all steps in the mRNA A natural mRNA display peptide library containing the
sequence X5CX5, constructed essentially as described
[28], was used to generate the hybrid drug-peptide li-*Correspondence: rroberts@its.caltech.edu
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Figure 1. Library Construction and Selection Scheme
(A) Construction of an mRNA-display library containing penicillin. A
fixed cysteine residue in the mRNA fusion library (–X5CysX5–) reacts
with sodium 6-bromoacetyl penicillanate to form a peptide-drug
conjugate. Figure 2. Efficiency and Specificity of the mRNA-Display-Penicillin
(B) In vitro selection cycle. A double-stranded PCR DNA library is Coupling Reaction
constructed, transcribed into mRNA, ligated with an oligonucleotide
(A) Electrophoretic analysis. Prior to treatment with sodium 6-bro-bearing a 3 puromycin (P), and translated in vitro to form the mRNA-
macetyl penicillanate, the RNase-treated mRNA-display librarypeptide fusion product. Reverse transcription and reaction with bro-
shows no interaction when (E166A) -lactamase is added (lane 1)moacetyl penicillin yields a cDNA/mRNA-peptide library bearing the
([35S]cysteine label). After coupling, approximately 20% of thedrug appended to the fixed cysteine. After reaction with PBP2a,
RNase-treated library moves with lower mobility, consistent withfunctional molecules are eluted with DTT, and the template is ampli-
attachment of the 30 kDa mutant lactamase (lane 2).fied by PCR for use in the next selection cycle.
(B) Specificity of library modification. The X5CX5 library and a control
template lacking cysteine were both reacted with sodium 6-bro-
moacetyl penicillanate ([35S]methionine label) and purified by inter-
action with immobilized (E166A) -lactamase as a function of time.brary. This starting library contained approximately
Approximately 20% of the fusion product is immobilized, while little1.5  1013 unique peptides, based on the efficiency of
or no binding is seen for the control template.
mRNA peptide fusion formation (data not shown), and
thus represented near saturation coverage for the flank-
ing random positions (ten random residues, 2010  1013). (Figure 2A). This analysis revealed that approximately
We confirmed the reduced state of the fixed cysteine 20% of the mRNA display library members contained a
by affinity purification on thiopropyl sepharose as in penicillin side chain and also demonstrated that a con-
previous work [9] (data not shown). trol mRNA display construct was unreactive with the
After coupling the library with sodium 6-bromoacetyl bromoacetyl derivative of the drug (Figures 2A and 2B).
penicillanate, we needed to address two issues: (1) the Therefore, our starting library contained3 1012 differ-
fraction of the library bearing the drug and (2) whether ent peptides bearing the drug as intended. Equally im-
any other functional groups on the peptide, RNA, or portant, the bromoacetyl drug was nonreactive with the
DNA were reactive with bromoacetyl moiety. The drug- functional groups on the template (hydroxyls, phos-
modified mRNA display library is indistinguishable from phates, ring nitrogens, exocyclic amines) and the non-
unmodified libraries in standard PAGE experiments be- cysteine amino acids (histidine, arginine, asparagine,
cause the molecular weight difference between them is glutamic and aspartic acid, serine, threonine, glutamine,
too small to be resolved. However, we were able to tyrosine, lysine, and tryptophan) as well as the N-ter-
accurately quantitate the amount of drug-modified li- minal amine in the peptide. Finally, these experiments
brary using a hydrolysis-deficient mutant of the RTEM-1 demonstrate that the penicillin side chain is capable of
-lactamase (E166A). This 30 kDa protein forms a stable covalent attachment interaction with the active site of
covalent adduct with penicillin and penicillin derivatives lactamase when covalently attached to a great variety
at serine 70 [29]. of peptide chains.
After library derivatization, we added the mutant
-lactamase (E166A) to the peptide fusion mixture and Selection for Interaction with PBP2a
separated library members that could form a covalent The penicillin-tagged fusion library was subjected to
iterative cycles of selection for binding immobilizedbond with the mutant -lactamase by electrophoresis
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found to contain a cysteine at the fixed position. Two
of the clones contained two cysteines, indicating that
multivalency may increase the chance of a particular
peptide to become attached, although this did not ap-
pear to be the predominant interaction mode in the li-
brary. We found no obvious sequence consensus be-
tween these clones, implying many distinct peptides
may be able to enhance the binding or reactivity of the
-lactam core.
Inhibition Activity of Selected Sequences
The peptide sequence LRNSNCIRHFF occurred twice
in the 15 clones and was chosen for our PBP2a inhibition
studies. We chemically synthesized milligram quanti-
ties of the peptide-penicillin conjugate (LRNSNC[Pen]-
IRHFF; Figure 4), purified the compound by HPLC, and
confirmed the identity of the product by mass spectrom-
etry (see Experimental Procedures). We also con-
structed a version of the peptide lacking the drug as a
negative control. To do this, we derivatized the central
cysteine moiety with bromoacetic acid to preclude the
intermolecular disulfide bond formation and mimic the
negative charge on the penicillin carboxylate (LRN
SNC[COOH]IRHFF; Figure 4). This blocked peptide
product was purified and analyzed as well. We then
sought an assay to compare the activity of (1) the pep-
tide-drug conjugate, (2) the blocked peptide, (3) the par-
ent penicillin (6-APA), and (4) cefotaxime, a cephalospo-
rin-based -lactam. The inhibition of penicillin binding
Figure 3. Results of mRNA-Display Selection proteins occurs via the following three-step mechanism:
(A) Progress of the selection experiment. The PBP2a binding in- (1) association and dissociation of the drug from the
creases in the eighth round and remains constant in the ninth round enzyme (Kd  k-1/k1), (2) covalent acylation of the active(green bar; [35S]methionine label]. The ninth-round mRNA-dispay
site serine (k2), and (3) deacylation of the enzyme (k3) [30].pool shows little or no binding to the empty matrix (red bar).
(B) Sequences of 15 clones from the library after nine cycles of
selection. A hyphen is shown for the fixed cysteine in the library PBPPen
Kd
>
< PBP•Pen
k2 ➤ PBP-Pen
and occurs in all the selected sequences. A dot is shown for dele-
tions, and mutations in the constant region are indicated with the k3
H2O
➤ PBPPenicilloateone-letter code. Cysteines occurring in the randomized regions are
indicated. The sequence used for inhibition testing is indicated in
red and appeared twice in the 15 clones. In general, the k3 is extremely slow (105 S1) for PBPs.
Covalent inhibition of the enzyme thus reflects only a
combination of binding (Kd  k1/k1) and reactivity (k2).PBP2a (Figures 1B and 3A). In each round, the library
was eluted specifically by liberating the PBP2a from the We measured covalent inhibition (IC50) using a compe-
tition-inhibition assay [31]. In this assay (Figure 5A), vari-matrix with DTT (see Experimental Procedures). As the
selection progressed, we gradually increased the strin- ous concentrations of drug are allowed to react with the
protein for a fixed time interval (15 min). Biotin-ampicillin,gency by decreasing the incubation time of the library
on the PBP2a matrix from 1 hr in the first cycle to 10 which can covalently attach to the active site serine, is
then added as a competitor, followed by quenching ofmin in the ninth cycle. Penicillin forms a stable adduct
with PBP2a, albeit very slowly under normal conditions. the reaction. The biotin-ampicillin-PBP2a conjugate can
then be detected via chemiluminescent Western blot-Our selection protocol thus selected for those members
that could bind and react efficiently. After eight cycles ting. Compounds that block or become covalently
attached to the active site of the protein decrease theof selection and amplification, the fraction of the library
bound to the PBP2a matrix rose significantly above amount of biotinylated ampicillin that becomes attached
to the protein, giving a characteristic inhibition curvebackground. An additional ninth cycle resulted in no
marked improvement. Under standard conditions where and a corresponding IC50. The IC50 measurement thus
represents a combination of both the equilibrium con-libraries were incubated for 30 min, the fraction of library
bound to the PBP2a increased from 0.4% of the first- stant for enzyme substrate complex formation (k1/k1) and
the formation of covalent drug-enzyme complexes (k2).cycle to 7% of the ninth-cycle library. This interaction
was specific for PBP2a, as little binding is seen when We found that the relative IC50 of this peptide conju-
gate (LRNSNC[Pen]IRHFF) in our assay conditions wasthe round nine library was tested with solid support
alone (0.6% binding; Figure 3A). about 7 mM, making it a better inhibitor of PBP2a than
either unconjugated peptide (LRNSNC[COOH]IRHFF)We cloned and sequenced 15 individuals from the
ninth-cycle library (Figure 3B). All of the sequences were (IC50  35 mM) or 6-aminopenicillanic acid (IC50  500
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Figure 4. Preparation and HPLC Chromato-
gram of Peptide-Penicillin Conjugate
(A) Peptide (LRNSNCIRHFF) reacts with so-
dium 6-bromoacetyl penicillanate or bro-
moacetic acid to produce peptide-penicillin
conjugate (LRNSNC[Pen]IRHFF) and blocked
peptide (LRNSNC[COOH]IRHFF), respec-
tively.
(B) The HPLC chromatogram is the superim-
posed image of traces from two runs. Com-
pound a is the peptide itself, and compound
b is the sodium 6-bromoacetyl penicillanate.
Product c is the peptide-penicillin conjugate.
The HPLC chromatogram indicates that the
conversion of peptide to peptide-penicillin
conjugate is quantitative and specific, as
100% peptide becomes conjugate without
any other side products.
mM) alone (Figure 5B). A control peptide conjugate (EQ The modest IC50 (7 mM) that we observe does not
necessarily imply that binding of our substrates is corre-KLIC[Pen]SEEDL) that did not appear in the final en-
riched library showed no such improvement (IC50  35 spondingly weak. First, the absolute value of the IC50
depends on the conditions chosen for the assay, withmM). Our results indicated that substitution of the peni-
cillin core with an appropriate 11-residue oligopeptide longer conjugate-PBP2a incubation times producing
correspondingly smaller IC50 values. Additionally, thegreatly enhanced the efficacy of the drug against PBP2a.
This enhancement likely occurs via interactions with the rate constant for covalent attachment of penams to
PBP2a (k2) is quite slow, ranging from k2  0.22 s1 forpeptide and the protein near the active site, as the un-
modified peptide also shows detectable activity. While benzyl penicillin to k2  0.0083 s1 for methicillin [30].
For comparison, the rate constant for formation of thethe peptide conjugate (LRNSNC[Pen]IRHFF) is more
than 100-fold improved compared to 6-APA, our se- acyl intermediate between penams and -lactamase is
2000 s1, 104- to 106-fold faster than PBP2a [33]. Cova-lected molecule is also comparable to cefotaxime (IC50
2.9 mM), a cephalosporin compound. Traditionally, the lent attachment of our compounds depends on the ratio
of k1/k2, as this value reflects how bound drug willcephalosporin core structure has been the starting point
for design of high-affinity inhibitors of PBP2a because partition between dissociation and product formation.
Values for k1, the formation rate constant, are typicallythese compounds are usually more potent against
PBP2a than penicillin systems. Recent structural work in excess of 108 M1s1 for penams interacting with
-lactamase [33]. If we presume that k1  k2 in orderon PBP2a indicates that the substituted cephalosporin
ring has additional van der Waals contacts with the active to give significant product formation, the predicted value
of Kd would be nanomolar or below. If we conservativelysite of PBP2a, providing higher affinity than the penicillin
ring system [32]. Our results imply that the selected pep- estimate that k1 is 106 M1s1, typical for macromolecular
association reactions, we predict values of Kd that aretides attaching to the 6 position of the penicillin moiety
are able to compensate for the absence of these extra micromolar or below. Overall, the biochemical analysis
indicates that the appended peptide facilitates the de-van der Waals interactions only seen in cephalosporin
systems by contacting the surface area of PBP2a. sired function of the drug by at least 100-fold. This ob-
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Figure 5. Functional Analysis of Penicillin and Penicillin-Drug Conjugates
(A) Scheme of competition assay with biotin-ampicillin and functionality of penicillin-peptide conjugates. The drug concentrations in the
inhibition assays were as follows: lane 1, 0 g/ml; lane 2, 2 g/ml; lane 3, 20 g/ml; lane 4, 200 g/ml; lane 5, 400 g/ml; lane 6, 2 mg/ml;
lane 7, 4 mg/ml; lane 8, 20 mg/ml; and lane 9, 40 mg/ml.
(B) Inhibition curves for the molecules tested.
servation is therefore consistent with our peptides add- of the cloned sequences were in-frame and contain a
cysteine residue at the fixed position. These observa-ing approximately 3 kcal to the stabilization (k1/k1), the
reactivity (k2), or some combination of the two to the tions are consistent with the idea that the peptide-
drug conjugate was formed and selected for interac-parent penam drug.
tion with the PBP2a, targeting our peptide library to
the active site of the protein. Chemical synthesis ofSignificance
the peptide-drug conjugate confirms that this com-
pound is in fact active against PBP2a, whereas bothOur overall goal in this work was to extend the chemi-
cal diversity possible in mRNA-display libraries through the drug and the peptide only show little or no activity
under concentrations that can be examined experi-creation of functional drug-peptide conjugates. To
that end, we have demonstrated that a penicillin side mentally.
Perhaps the most compelling aspect of these exper-chain may be appended to a mRNA-display library
in a chemically orthogonal fashion with reasonable iments is their generality. There are numerous exam-
ples where drugs target specific sites in proteins [34,synthetic efficiency. After the nine-round selection, all
Chemistry & Biology
238
ommended by the manufacturer (New England Biolabs). The PBP2a35]. The ability to generate peptide-drug conjugates
protein was cleaved from beads with 50 mM DTT in column bufferenables the use of small molecules to direct display
(20 mM HEPES, pH 8.0; 500 mM NaCl; 1 mM EDTA) and dialyzedlibraries to a particular face or site in a protein target
against phosphate buffer (50 mM, pH 8.0) overnight.
of interest. Additionally, the covalent derivatization The pure PBP2a was reacted with biotin-SS-(sulfo)-NHS (Pierce
strategy we have used here enables library construc- Chemical; 10 mM in 50 mM phosphate buffer, pH 8.0) and dialyzed
against phosphate buffer (50 mM, pH 8.0). The resulting biotinlyatedtion using compounds that would not be possible via
PBP2a was incubated with streptavidin agarose gel (Pierce Chemi-in vitro nonsense suppression [17]. For example, com-
cal) and shaken for 30 min. The supernatant was removed, and thepounds that strongly inhibit translation, such as kinase
resulting PBP2a agarose was washed with phosphate buffer. Theinhibitors or GTP analogs, or side chains that might
fusion conjugate was mixed with immobilized PBP2a agarose in 1
be too large to fit in the exit tunnel of the ribosome (e.g., ml of incubation buffer (50 mM phosphate, pH 8.0; 100 mM NaCl;
a heme) may not be efficiently inserted via nonsense 2 mM biotin) and incubated for variable time (cycle 1–3, 1 hr; cycle
4–7, 30 min; cycle 8 and 9, 10 min). The agarose then was washedsuppression. We therefore anticipate that our ap-
six times with 500 l washing buffer (50 mM phosphate, pH 8.0; 100proach should be broadly applicable for the develop-
mM NaCl; 0.1% Triton X-100). Five hundred microliters cleavagement of novel tools to control biochemical processes.
buffer (50 mM phosphate, pH 8.0; 100 mM NaCl; 100 mM DTT)
was incubated with washed agarose for 1 hr. The supernatant wasExperimental Procedures
collected, desalted, concentrated with microcon YM-30 (Milipore),
and used for PCR amplification directly with sd2 and sd3 as primers.Preparation of Sodium 6-Bromoacetyl Penicillanate
Four hundred thirty-two milligrams of 6-aminopenicillanic acid
Relative IC50 Assay of Peptide Penicillanate Conjugates(Sigma; 6-APA, 2 mM) and 500 mg sodium bicarbonate (Sigma; 4.5
The selected peptides were synthesized in an ABI peptide synthe-mM) were mixed in 4 ml water and 2 ml acetone with stirring for 10
sizer with Fmoc chemistry, deprotected with TFA, and purified bymin at 0	C. Four hundered four milligrams of bromoacetyl bromide
HPLC. The lyophilized peptides were reacted with sodium bro-(Aldrich; 2 mM, 175 l) was dissolved in 2 ml of acetone and added
moacetyl penicillanate in sodium borate buffer (100 mM, pH 8.3).to the stirring solution. The reaction flask was wrapped with alumi-
The conjugates of peptide with -lactam were purified again bynum foil and kept on ice for 10 min more. The solution was removed
HPLC and lyophilized. Various concentrations of conjugates werefrom the ice bath and allowed to come to room temperature. The
prepared by dissolving in reaction buffer (50 mM phosphate, pH 8.0;reaction was stirred for 1 hr, and 5 ml of water was added to dissolve
100 mM NaCl) and incubating with 2 g pure PBP2a, respectively, atany residual white salt in the flask. The reaction was extracted twice
37	C for 15 min. Biotin-ampicillin (20 g/ml) was added immediatelywith ether (4 ml) and then covered with 5 ml ethyl acetate. The
and incubated at 37	C for 10 min. The reaction was stopped byreaction mixture was acidified with 40% phosphoric acid with stir-
heating the reaction mixture at 94	C for 5 min. The samples werering at 0	C. The ethyl acetate layer was removed, extracted (3)
loaded into 12% SDS-PAGE for separation, then transferred to awith 5 ml distilled water, and dried over anhydrous magnesium
nitrocellulose membrane by blotting with sodium bicarbonate buffersulfate. The dried reaction mixture was combined with 300 l
(20% methanol; 3 mM Na2CO3; 10 mM NaHCO3) at 400 mA for 3 hr.n-butanol containing sodium 2-ethylhexanoate and stirred for 30
The membranes was blocked with blocking solution (20 mM Tris,min. The precipitate was collected by filtration, washed with several
pH 8.0; 150 mM NaCl; 0.05% Tween-20; 5% milk) for 1 hr, thenportions of ethyl acetate, and air dried (395 mg). The ESI-MS gives
incubated with 10 ml TBS buffer (20 mM Tris, pH 8.0; 150 mM NaCl)two equal peaks at 335.0 and 337.0. (The expected mass peaks
containing 1 g/ml streptavidin-HRP protein (Pierce Chemical) at[M  H] are 334.97 and 336.97.)
room temperature for 1 hr. The membrane was washed with 50 ml
TBS buffer six times at 5 min intervals and covered with femto-Preparation of mRNA-Peptide -Lactam Fusion
Western blotting reagent (Pierce Chemical). The membrane wasA synthetic DNA library template sd7 (ACTATTTACAACCACCATG
then detected under the digital camera in the dark to collect chemilu-NNSNNSNNSNNSNNSTGCNNSNNSNNSNNSNNSGGCGGCGACT
minescent emissions for 10–15 min.AAGGACGACGATGACAAGGCGGCGGCGGC) was purified by pre-
parative polyacrylamide gel electrophoresis and amplified by poly-
Acknowledgmentsmerase chain reaction (PCR) with the primers sd2 (GGATTCTAATAC
GACTCACTATAGGGACAATTACTATTTACAACCACCATG) and sd3
We thank William J. Ja for proofreading and comments on the manu-(GCCGCCGCCGCCCTTGTCATCGTCGTCCTTGTAGTC). The resulting
script and Professor K. Hiramatsu (Juntendo University, Japan) fordouble-stranded DNA template was used to prepare the mRNA
kindly providing us with the PBP2a gene. This work was supporteddisplay fusion library as previously described [28]. After purification
by NIH grant GM60416 (R.W.R.).with oligo-dT cellulose (New England Biolabs), the fusions were
used as templates for reverse transcription at conditions recom-
Received: December 20, 2002mended by the manufacturer (Superscript II RNase H reverse tran-
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